



EXPRESS MAIL CERTIFICATE

"Express Mail" Label No. : EV 367 775 125 US
Serial No. : 10/091,609
Applicant(s) : MJALLI, Adnan M.M. et al.
Filing Date : March 5, 2002
Title: : BENZIMIDAZOLE DERIVATIVES AS
THERAPEUTIC AGENTS
Examiner : Laura Stockton
Group Art Unit : 1626
Type of Document(s) : Express Mail Certificate;
Transmittal Form;
Amendment and Response (18 Pages); and
Return Postcard

I hereby certify that the documents identified above are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and are addressed to Mail Stop Non-Fee Amendment, Commissioner for Patents, P O Box 1450, Alexandria, VA 22313-1450.

Carol McCabe (signature)
Carol McCabe

Date Mailed: June 9, 2004



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/091,609	
	Filing Date	March 5, 2002	
	First Named Inventor	MJALLI, Adnan M.M. et al.	
	Art Unit	1626	
	Examiner Name	Laura Stockton	
Total Number of Pages in This Submission	4	Attorney Docket Number	41305-271622

ENCLOSURES (check all that apply)				
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): See Remarks Below		
<table border="1"><tr><td>Remarks</td><td>Express Mail Certificate EV 367 775 125 US; Transmittal Form; Return Postcard</td></tr></table>			Remarks	Express Mail Certificate EV 367 775 125 US; Transmittal Form; Return Postcard
Remarks	Express Mail Certificate EV 367 775 125 US; Transmittal Form; Return Postcard			

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Samuel B. Rollins, Reg. No. 52,180, Kilpatrick Stockton LLP
Signature	
Date	June 9, 2004

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name			
Signature		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

06-10-04

Express Mail Cert. No. EV 367 775 125 US

APR 1626
ifw



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Adnan M. M. Mjalli et al.
Serial No. : 10/091,609
Filing Date : March 5, 2002
For : BENZIMIDAZOLE DERIVATIVES AS
THERAPEUTIC AGENTS
Examiner : Laura Stockton
Art Unit : 1626

Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Amendment and Response

Sir:

This Response is being submitted in response to the Office Action mailed
April 14, 2004.

Amendments to the Claims are reflected in the listing of the claims which begins on
page 2 of this paper.

Remarks begin on page 15 of this paper.